Research
Hormonal
BPC-157 and TB-500 enhance tissue repair and angiogenesis in aged tissues, showing promise in small pilot studies for chronic pain and wound healing.
BPC-157 and TB-500 are peptides that may help heal tissues, tendons, and muscles by promoting blood vessel growth and reducing inflammation. Small studies suggest they can relieve chronic pain and heal wounds, but they are not FDA-approved for these uses, and long-term safety is unknown.
LimitedQualifiesLOW confidence
BPC-157... promotes tissue repair through activation of angiogenic pathways... Clinical pilot data derived from distinct populations indicated that 58% of elderly patients with chronic knee pain achieved sustained pain relief beyond 6 months following a single injection... TB-500... promotes cell migration to injury sites, enhances angiogenesis via VEGF upregulation, and releases anti-inflammatory mediators.
Why this rating
Evidence is from animal studies and small human pilot studies (n=12-58); no large RCTs.
Source
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Volodymyr Mavrych et al. · Frontiers in Aging · 2026
DOI 10.3389/fragi.2026.1790247
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves metabolic parameters associated with biological aging by restoring glycemic control and reducing visceral adiposity.Strong
- CJC-1295 and Ipamorelin restore youthful growth hormone secretion patterns by preserving physiological pulsatility, avoiding the adverse effects of continuous exogenous GH administration.Moderate
- Epitalon, a tetrapeptide, extends cellular lifespan by activating telomerase and lengthening telomeres, while also modulating pineal gland function to restore melatonin synthesis.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →